LTGO insider transaction filings

Name: LTGO insider transaction filings (SEC Form 4)
Creator: FilingPulse
License: https://www.sec.gov/edgar

Latigo Biotherapeutics, Inc. — 7 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen LTGO transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 7 insiders — 280,000 shares, $5,040,000 total (shares × price as filed).
Open-market sales (code S, non-derivative): none reported.
Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
Largest priced transaction: purchase of 140,000 shares @ $18.00 ($2,520,000) by Foresite Capital Management V, LLC, filed 2026-08-10.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

Insider	Filings	Purchases (P)	Sales (S)	Other legs
Foresite Capital Management V, LLC — 10% owner & Foresite Capital Fund V, L.P. — 10% owner & Foresite Capital Opportunity Management V, LLC — 10% owner & Foresite Capital Opportunity Fund V, L.P. — 10% owner & Foresite Capital Management VI LLC — 10% owner & Foresite Capital Fund VI LP — 10% owner	1	1 leg · 140,000 sh · $2,520,000	—	14
Tananbaum James B. — Director, 10% owner	1	1 leg · 140,000 sh · $2,520,000	—	14
SEIDENBERG BETH C — Director, 10% owner	1	—	—	14
Westlake BioPartners Fund I, L.P. — 10% owner & Westlake BioPartners GP I, LLC — 10% owner & Westlake BioPartners Fund II, L.P. — 10% owner & Westlake BioPartners GP II, LLC — 10% owner & Westlake BioPartners Opportunity Fund I, L.P. — 10% owner & Westlake BioPartners Opportunity GP I, LLC — 10% owner	1	—	—	14
5AM Ventures VI, L.P. — 10% owner & 5AM Partners VI, LLC — 10% owner & 5AM Opportunities II, L.P. — 10% owner & 5AM Opportunities II (GP), LLC — 10% owner & PARMAR KUSH — 10% owner & Schwab Andrew J. — 10% owner	1	—	—	6
Sanofi — 10% owner	1	—	—	4
SMITH TODD N — Director	1	—	—	1

Recent Form 4 filings — Latigo Biotherapeutics, Inc.

Filed	Form	Insider	Reported transactions	Source
2026-08-12	4	5AM Ventures VI, L.P. — 10% owner 5AM Partners VI, LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner PARMAR KUSH — 10% owner Schwab Andrew J. — 10% owner	Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0	EDGAR
2026-08-12	4	Sanofi — 10% owner	Conversion (C): 494,800 · Conversion (C): 177,978 · Conversion (C): 494,800 (derivative) · Conversion (C): 177,978 (derivative)	EDGAR
2026-08-11	4	Westlake BioPartners Fund I, L.P. — 10% owner Westlake BioPartners GP I, LLC — 10% owner Westlake BioPartners Fund II, L.P. — 10% owner Westlake BioPartners GP II, LLC — 10% owner Westlake BioPartners Opportunity Fund I, L.P. — 10% owner Westlake BioPartners Opportunity GP I, LLC — 10% owner	Conversion (C): 938,979 · Conversion (C): 3,547,842 · Conversion (C): 1,027,635 · Conversion (C): 3,464,072 · Conversion (C): 1,484,401 · Conversion (C): 165,519 · +8 more	EDGAR
2026-08-10	4	Foresite Capital Management V, LLC — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner Foresite Capital Management VI LLC — 10% owner Foresite Capital Fund VI LP — 10% owner	Conversion (C): 3,117,664 @ $0 · Conversion (C): 445,320 @ $0 · Conversion (C): 1,125,823 @ $0 · Conversion (C): 742,201 @ $0 · Purchase (P): 140,000 @ $18 · Conversion (C): 195,776 · +9 more	EDGAR
2026-08-10	4	SEIDENBERG BETH C — Director, 10% owner	Conversion (C): 938,979 · Conversion (C): 3,547,842 · Conversion (C): 1,027,635 · Conversion (C): 3,464,072 · Conversion (C): 1,484,401 · Conversion (C): 165,519 · +8 more	EDGAR
2026-08-10	4	Tananbaum James B. — Director, 10% owner	Conversion (C): 3,117,664 · Conversion (C): 445,320 · Conversion (C): 1,125,823 · Conversion (C): 742,201 · Purchase (P): 140,000 @ $18 · Conversion (C): 195,776 · +9 more	EDGAR
2026-08-10	4	SMITH TODD N — Director	Grant/award (A): 105,542 (derivative) @ $0	EDGAR

Recent 8-K events — Latigo Biotherapeutics, Inc.

Filed	Form	Items reported	Source
2026-09-03	8-K	2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits	EDGAR
2026-08-10	8-K	5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits	EDGAR

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=LTGO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →